Every monsoon and winter, hospitals see a rise in babies struggling with severe cough, breathing trouble, or symptoms that seem like an upper respiratory tract infection or pneumonia. Many parents ...

Whooping cough cases in Mississippi have reached a 16-year high, with 139 cases reported in 2025. Children ages 5-17 and infants under one year old are the most affected by the whooping cough outbreak ...

New Centers for Disease Control and Prevention data is showing that newly released RSV vaccines are highly effective at keeping infants from becoming hospitalized. The CDC says nirsevimab was 90% ...

INDIANAPOLIS (WISH) — This week, it was reported that the FDA is reviewing the safety of two drugs, Clesrovimab (Enflonsia) and Nirsevimab (Beyfortus), both approved for the prevention of RSV in ...

• RSV is the leading cause of infant hospitalization in the U.S. • Health officials urge vaccination for pregnant women, seniors, and people with medical risks. • Cases are climbing nationwide as flu ...

Clesrovimab-cfor provides a fixed 105-mg dose, simplifying administration and offering five months of protection against RSV in infants. The CLEVER trial demonstrated a 60.5% reduction in ...

Because respiratory syncytial virus is spreading at unusually high levels for this time of year, Pennsylvania and New Jersey have extended their window for infants and toddlers be immunized against ...

TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech ...

In response to the global burden of severe respiratory syncytial virus (RSV) disease among infants, the World Health Organisation (WHO) has released its first position paper recommending the global ...

Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein. Data regarding the safety and efficacy of clesrovimab in ...